TL
Tiziana Life Sciences Ltd
TLSA · NASDAQ
$0.89 -0.01% (-$0.00)
1M -21.34%
Market Cap $58.5M
P/E Ratio -
Div. Yield -
ROE 490.09%
Bulios Fair Price
$0.63
29.2% downside
Current Price
$0.89
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TLSA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 1,124.90x
P/FCF N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 86.15%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 160.34%
ROIC 4,189.76%
Debt
5 /100
High Current ratio 0.76x
Int. coverage -1,182.44x
Debt/Equity 8.77x
Stability
41 /100
Moderate EPS volatility 47.65%
Profitable years 0
Beta 0.45x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TLSA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Ivor R. Elrifi
Employees
10
Headquarters
London